Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus pembrolizumab in squamous NSCLC
NCT03157089Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of afatinib in squamous cell carcinoma of the lung (LSCC), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Response Rate up to 556 days. Started Nov 2017; status: completed.
02
Drugs
afatinib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03157089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157089.